Conduit Pharmaceuticals (NASDAQ:CDT) has announced that the first phase in its collaboration with Sarborg, aimed at integrating advanced AI and cybernetics technology into its operations has been completed.
The company stated that this collaboration represents a transformative step in its approach to drug development and delivery. Conduit aims to streamline drug repurposing, accelerate drug discovery, optimize solid-form identification, and enhance the precision and efficiency of clinical trial monitoring. These advancements are expected to reduce timelines, lower costs, and improve the predictability of successful outcomes.
According to Conduit, AI-driven processes are projected to minimize resource-intensive steps, resulting in significant cost savings and enabling the development of novel therapeutics that were previously constrained by traditional methods. The company is currently focused on Phase 2 clinical trials for auto-immune disorders.
